Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study ; volume:24 ; number:1 ; day:4 ; month:6 ; year:2022 ; pages:1-11 ; date:12.2022
Arthritis Research & Therapy ; 24, Heft 1 (4.6.2022), 1-11, 12.2022
- Creator
-
Schmitt, Christophe
Brockwell, Laura
Giraudon, Mylène
Zucchetto, Mauro
Christ, Lisa
Bannert, Bettina
Daikeler, Thomas
Villiger, Peter Matthias
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-022-02815-9
- URN
-
urn:nbn:de:101:1-2022080220550499536816
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schmitt, Christophe
- Brockwell, Laura
- Giraudon, Mylène
- Zucchetto, Mauro
- Christ, Lisa
- Bannert, Bettina
- Daikeler, Thomas
- Villiger, Peter Matthias
- SpringerLink (Online service)
Other Objects (12)
Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab for relapsing and remitting giant cell arteritis: a case series
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial
Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations
Takayasu arteritis in children
Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab for relapsing and remitting giant cell arteritis: a case series
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial
Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations
Takayasu arteritis in children
Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab for relapsing and remitting giant cell arteritis: a case series
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial
Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations